✦ LIBER ✦
Teplizumab (Anti-CD3 mAb) Treatment Preserves C-Peptide Responses in Patients With New-Onset Type 1 Diabetes in a Randomized Controlled Trial: Metabolic and Immunologic Features at Baseline Identify a Subgroup of Responders
✍ Scribed by Herold, K. C.; Gitelman, S. E.; Ehlers, M. R.; Gottlieb, P. A.; Greenbaum, C. J.; Hagopian, W.; Boyle, K. D.; Keyes-Elstein, L.; Aggarwal, S.; Phippard, D.; Sayre, P. H.; McNamara, J.; Bluestone, J. A.
- Book ID
- 120656212
- Publisher
- American Diabetes Association
- Year
- 2013
- Tongue
- English
- Weight
- 932 KB
- Volume
- 62
- Category
- Article
- ISSN
- 0012-1797
No coin nor oath required. For personal study only.